Furthermore, depletion of CD163+ TAMs led to restoration of cytotoxic T-cell and inflammatory monocyte activity, leading to resensitization of tumor cells to anti-PD-1 therapy (265). This evidence concerns the gene PDCD1 and neoplasm.